PROPHYLACTIC PLATELET DOSE STRATEGY TO PREVENT BLEEDING IN THROMBOCYTOPENIA

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。由于血小板使用率继续以不成比例地高于红细胞的速度增加，因此确定提供血小板支持的最具成本效益的策略非常重要。确定和实施最安全和最具成本效益的血小板支持策略对于有效的疾病管理而不消耗血小板供应至关重要。本研究的主要目的是比较高、中和低剂量血小板治疗的三个研究组中至少发生一次2级或以上出血事件的患者百分比，根据血小板剂量试验出血量表确定。次要目的是比较三个研究组的血小板和止血相关结局（即，血小板利用率、输血频率、血小板支持天数、至首次2+级出血的天数、研究期间出血的最高类别、出血严重程度等）。还将进行成本分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As platelet use continues to increase at a rate disproportionately higher than that of red blood cells, it is important to identify the most cost-effective strategies for providing platelet support. Identification and implementation of the most safe and cost effective strategies for providing platelet support is crucial for effective disease management without depleting platelet supplies. The primary objective of this study is to compare the three study arms of high, medium, and lower dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding, as determined by the Platelet Dose Trial Bleeding Scale. Secondary objectives are to compare the three study arms with respect to platelet and hemostasis related outcomes (i.e., platelet utilization rates, frequency of transfusions, days of platelet support, number of days to first Grade 2+ bleeding, highest category of bleeding during time on the study, bleeding severity, etc.). A cost analysis will also be conducted.